β-Catenin and K-Ras Mutations and RASSF1A Promoter Methylation in Taiwanese Colorectal Cancer Patients

2012 ◽  
Vol 16 (11) ◽  
pp. 1277-1281 ◽  
Author(s):  
Shee-Ping Chen ◽  
Chang-Chieh Wu ◽  
Sung-Ying Huang ◽  
Jung-Cheng Kang ◽  
Sheng-Chun Chiu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Ras Mutations ◽  
Colorectal Cancer Patients

scholarly journals Promoter methylation of Wnt antagonistsDKK1andSFRP1is associated with opposing tumor subtypes in two large populations of colorectal cancer patients

2011 ◽  
Vol 32 (5) ◽  
pp. 741-747 ◽  
Author(s):  
James B. Rawson ◽  
Michael Manno ◽  
Miralem Mrkonjic ◽  
Darshana Daftary ◽  
Elizabeth Dicks ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Tumor Subtypes ◽  
Large Populations ◽  
Colorectal Cancer Patients

scholarly journals KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan: Molecular spectrum, frequency and distribution pattern

2019 ◽  
Author(s):  
Muhammad Awidi ◽  
Nidaa Ababneh ◽  
Maha Shomaf ◽  
Feras Al Fararjeh ◽  
Laila Owaidi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Distribution Pattern ◽  
Cancer Patients ◽  
Molecular Spectrum ◽  
Kras Mutations ◽  
Exon 2 ◽  
Ras Mutations ◽  
Colorectal Cancer Patients ◽  
Kras Exon

Abstract Background A constitutively active RAS protein in the absence of stimulation of the epidermal growth factor receptor (EGFR) is the result of mutations in KRAS and NRAS genes. Mutations in the KRAS exon 2 and outside exon 2 have been found to predict the resistance to anti-EGFR monoclonal therapy. A substantial proportion of metastatic colorectal cancer cases (mCRC) exhibit RAS mutations outside KRAS exon 2, particularly in KRAS exon 3 and 4 and NRAS exons 2, 3. No data about RAS mutations outside KRAS exon 2 are available for Jordanian patients with mCRC. We aim to study the molecular spectrum, frequency, and distribution pattern of KRAS and NRAS mutations in Jordanian patients with mCRC. Methods A cohort of 190 Jordanian metastatic colorectal cancer patients were enrolled in the trial. We detected mutations in exon 2 of the KRAS and NRAS gene as well as mutations outside of exon 2 using the StripAssay technique. The KRAS StripAssay covered 29 mutations and 22 NRAS mutations. Results Mutations were observed in 92 (48.42%) cases, and KRAS exon 2 accounted for 76 cases (83.69%). KRAS G12D was the most common mutation, occurring in 18 cases, followed by KRAS G12A in 16 cases, and G12T in 13 cases. Mutations outside of KRAS exon 2 represented 16.3% of the mutated cases. Among those, 6 cases (6.48%) carried mutations in NRAS exon 2, 3 and 10 cases (10.87%) in KRAS exon 3 and 4. Conclusion The frequency of NRAS and KRAS mutations outside of exon 2 appears to be higher in Jordanian patients in comparison with patients from western countries. KRAS mutations outside of exon 2 should be tested routinely to identify patients who should not be treated with anti-EGFR antibodies.

scholarly journals Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients.

Gut ◽  
1995 ◽  
Vol 36 (1) ◽  
pp. 81-86 ◽  
Author(s):  
J Smith-Ravin ◽  
J England ◽  
I C Talbot ◽  
W Bodmer
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Sporadic Colorectal Cancer ◽  
Ras Mutations ◽  
Faecal Samples ◽  
Colorectal Cancer Patients

Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15123-e15123
Author(s):  
Joana Vidal ◽  
Alba Dalmases ◽  
Maria Carmen Vela ◽  
Maria Merce Muset ◽  
Gabriel Piquer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Ras Mutations ◽  
Colorectal Cancer Patients

scholarly journals Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients

2003 ◽  
Vol 105 (4) ◽  
pp. 491-493 ◽  
Author(s):  
Hiroshi Nakayama ◽  
Kenji Hibi ◽  
Tsunenobu Takase ◽  
Taiji Yamazaki ◽  
Yasushi Kasai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Molecular Detection ◽  
Recurrent Colorectal Cancer ◽  
Colorectal Cancer Patients

scholarly journals Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Andrea J. Savio ◽  
Darshana Daftary ◽  
Elizabeth Dicks ◽  
Daniel D. Buchanan ◽  
Patrick S. Parfrey ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Colorectal Cancer Patients ◽  
Two Populations

MLH1 Promoter Methylation, Diet, and Lifestyle Factors in Mismatch Repair Deficient Colorectal Cancer Patients From EPIC-Norfolk

2011 ◽  
Vol 63 (7) ◽  
pp. 1000-1010 ◽  
Author(s):  
Laura J. Gay ◽  
Mark J. Arends ◽  
Panagiota N. Mitrou ◽  
Richard Bowman ◽  
Ashraf E. Ibrahim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Mismatch Repair ◽  
Promoter Methylation ◽  
Lifestyle Factors ◽  
Mlh1 Promoter ◽  
Colorectal Cancer Patients ◽  
Diet And Lifestyle

scholarly journals K-ras Mutations in the Plasma of Colorectal Cancer Patients

2010 ◽  
Vol 41 (3) ◽  
pp. 156-158 ◽  
Author(s):  
Yong-qi Shen ◽  
Yun-bin Ye ◽  
Xiong-wei Zheng ◽  
Chao Li ◽  
Qiang Chen
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Ras Mutations ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document